Medical Xpress

Targeting protein BCL-2 may create a promising pathway to reversing pulmonary fibrosis

Researchers at National Jewish Health and collaborating institutions have uncovered a critical mechanism driving persistent pulmonary fibrosis and identified a promising strategy to reverse it. The ...
ascopubs.org

Strategies to overcoming rituximab-chemotherapy resistance by targeting the autophagy pathway using bortezomib in combination with the Bcl-2 inhibitor obatoclax in non-Hodgkin ...

Panobinostat plus lenalidomide and dexamethasone phase I trial in multiple myeloma (MM) We found that repeated rituximab exposure leads to deregulation of Bcl-2 proteins and concomitant chemotherapy ...
Yahoo Finance

Game-Changing BCL-2 Inhibitors Set to Revolutionize Cancer Treatment Market | DelveInsight

New York, USA, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Game-Changing BCL-2 Inhibitors Set to Revolutionize Cancer Treatment Market | DelveInsight DelveInsight's BCL-2 Inhibitor Market Insights report ...
EurekAlert!

Structure-destabilizing mutations transform Bcl-2 from an antiapoptotic protein into a proapoptotic protein

Bcl-2 family proteins are highly conserved molecules that play a crucial role in regulating the release of apoptotic proteins from mitochondria. They possess Bcl-2 homology (BH) domains, which are ...
ascopubs.org

A phase 1/2 dose escalation study of the BCL-2 inhibitor ZN-d5 and the WEE1 inhibitor azenosertib (ZN-c3) in patients (Pts) with acute myeloid leukemia (AML).

A phase II study of vibecotamab, a CD3-CD123 bispecific T-cell engaging antibody, for MRD-positive AML and MDS after hypomethylating agent failure. This is an ASCO Meeting Abstract from the 2023 ASCO ...